Is canakinumab’s patent protection still in effect?
Yes—at least some patent protection for canakinumab (Ilaris) is still expected to remain in force in many countries, because the key patents underpinning the drug are not tied to a single universal expiration date and can vary by jurisdiction due to differences in filing dates, extensions, and regulatory adjustments (for example, supplementary protection certificates where available). The exact status depends on the country you care about.
What determines whether the patents are still “in effect”?
Patent protection timing for canakinumab can differ based on:
- The country (patent filing and grant timelines vary).
- Whether a supplementary protection certificate (SPC) is available and granted (common in parts of Europe).
- The specific patent family being considered (some expire earlier than others).
- Whether any patents cover additional formulations, new uses, dosing regimens, or manufacturing/process aspects beyond the original active-ingredient claims.
Because “canakinumab’s patent protection” could refer to multiple overlapping patents, you typically need a country-by-country patent search keyed to the reference product and the specific patent numbers.
Why people ask this: when could cheaper versions arrive?
When patent protection is still active, generic substitution usually cannot proceed for the protected aspects of the product. For biologics like canakinumab, the relevant competitive timeline is often influenced by:
- Expiry of composition/use patents.
- Expiry of related manufacturing/process patents.
- Regulatory exclusivity rules (which may extend beyond patent expiry, depending on the jurisdiction).
What you can do next to get a definitive answer
To determine whether protection is currently in effect for your location, the most reliable approach is to check:
1) the specific country/region (e.g., US, EU, UK, Canada, Japan), and
2) the patent register for the canakinumab reference product (Ilaris), including any SPCs and relevant related patent families.
If you tell me the country (or region) you’re interested in, I can narrow the answer to the most likely in-force protections and what that means for market entry there.